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Abstract
Motivation: Identifying genes with bimodal expression patterns from large-scale expression profiling data is an important analytical 
task. Model-based clustering is popular for this purpose. That technique commonly uses the Bayesian information criterion (BIC) for 
model selection. In practice, however, BIC appears to be overly sensitive and may lead to the identification of bimodally expressed 
genes that are unreliable or not clinically useful. We propose using a novel criterion, the bimodality index, not only to identify but also 
to rank meaningful and reliable bimodal patterns. The bimodality index can be computed using either a mixture model-based algorithm 
or Markov chain Monte Carlo techniques.
Results: We carried out simulation studies and applied the method to real data from a cancer gene expression profiling study. 
Our findings suggest that BIC behaves like a lax cutoff based on the bimodality index, and that the bimodality index provides an 
objective measure to identify and rank meaningful and reliable bimodal patterns from large-scale gene expression datasets. R code to 
compute the bimodality index is included in the ClassDiscovery package of the Object-Oriented Microarray and Proteomic Analysis 
(OOMPA) suite available at the web site http;//bioinformatics.mdanderson.org/Software/OOMPA. Wang et al
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Introduction
Identifying genes with bimodal expression patterns 
from  large-scale  expression  profiling  data  is  an 
important  task.  Bimodal  expression  patterns  can 
result naturally from differential expression, with the 
two modes centered on the mean expression of a gene 
in two distinct subgroups of samples. In the context 
of  cancer,  bimodal  expression  patterns  can  result 
from  genomic  lesions  that  occur  in  some  patients 
but not others. For example, Tomlins and colleagues1 
noticed  that  the  ETV1  gene  was  overexpressed  in 
10%–20%  of  prostate  cancer  samples  in  multiple 
data sets and that the ERG gene was overexpressed 
in about 40% of prostate cancer samples in the same 
datasets.  They  further  noticed  that  overexpression 
of these two genes was mutually exclusive. These 
findings led them to discover that the overexpression 
was driven by recurrent translocations that fused the 
androgen-responsive  gene  TMPRSS2  either  with 
ETV1 (in some cases) or with ERG (in other cases).
The definition of a bimodal distribution can be vague: 
the term typically refers to a mixture of two populations 
with distinct means. In density estimation, a bimodal 
distribution can be recognized by the presence of two 
modes, each with a characteristic peak. Determining 
the factor that characterizes the samples that belong 
to  each  of  the  two  distributions  can  be  difficult. 
In the realm of large-scale gene expression profiling, 
finding bimodal expression patterns is an important 
analytical process. In oncology, this process may be 
part of the search for clinically important therapeutic 
targets within tumors. The process can also reveal 
molecular signatures that distinguish tumor subtypes, 
which contributes to our understanding of the clinical 
and biologic characteristics of cancer.
A  two-component  normal  mixture-model-based 
clustering algorithm is commonly used to discover 
bimodal  expression  patterns.  In  contrast  to  other 
clustering  methods,  this  approach  is  based  on  a 
mixture  of  statistical  distributions  in  which  each 
component represents a cluster. The method converts a 
classification problem into a statistical estimation of the 
mixture density. The approach has proven to be useful 
in a wide range of applications, including microarray 
gene expression analysis.2–6 The technique is sensitive 
and allows for rapid computation. A major benefit of 
the mixture model-based clustering technique is that 
the algorithm characterizes each cluster and provides 
probabilities of cluster membership. In addition, the 
algorithm provides point estimates of the statistical 
parameters including the means, standard deviations, 
and sample proportions in each group.
One difficulty with its application is finding an 
appropriate  test  statistic  to  estimate  p-values  and 
choosing  a  suitable  cutoff  to  minimize  the  false 
discovery rate. The log likelihood ratio test (LRT) 
statistic  could  be  adopted  to  test  the  hypothesis 
H1  that  gene  expression  distribution  is  a  bimodal, 
against the null hypothesis H0 that the distribution 
is  unimodal.  Under  the  null  hypothesis,  the 
LRT  asymptotically  has  a  chi-squared  distribution 
(-2 log λ ∼ χ2). However, in practice, the chi-squared 
distribution, with two degrees of freedom, seems to 
converge  slowly.  Consequently,  the  critical  value 
from chi-square table is too small, so it over-rejects, 
or inflates the false positive rate.7 Recently Ertel and 
Tozeren  applied  a  two-component  normal  mixture 
model to identify bimodal genes and their potential 
roles in cell signaling and disease progression.8 They 
used  LRT,  with  p-values  estimated  by  evaluating 
the chi-square distribution with six degree of freedom, 
in order to get more conservative p-values. To identify 
significant  bimodal  genes,  an  ad-hoc  p-value  was 
selected.
Researchers  combine  mixture-model-based 
clustering with either the Akaike information criterion 
(AIC)  or  the  Bayesian  information  criterion  (BIC). 
Both  criteria  impose  arbitrary  penalties  based  on 
the  number  of  parameters  to  determine  whether 
a  unimodal  or  bimodal  model  is  a  better  fit  to  the 
observed data. A dataset is identified as bimodal if the 
parameter penalties are outweighed by the increased 
likelihood  of  the  bimodal  model.  Although  useful, 
according to our experience, the reliance on AIC or 
BIC appears to be overly sensitive in its application 
to  gene  expression  profiling  data  and  may  lead  to 
the identification of numerous genes whose bimodal 
patterns  cannot  be  confirmed  in  follow-up  studies. 
In order to be clinically useful in practice, a bimodal 
pattern should exhibit significant separation between 
the means of the two groups and should have adequate 
sample  sizes  in  each  group.  In  applications  of  the 
mixture-model-based clustering technique, researchers 
frequently find it necessary to use subjective ad hoc 
cutoffs in addition to the AIC or BIC in order to reveal 
reliable and meaningful bimodal patterns.The bimodality index
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For identifying bimodal expressed genes, a practical 
method  was  introduced  previously  by  Andrew 
and  colleagues,9  called  Profile  Analysis  using 
Clustering  and  Kurtosis  (PACK).  PACK  has  two 
steps; (1) using the expectation-maximization (EM) 
algorithm, a common method for finding maximum 
likelihood  estimates  of  parameters  in  probabilistic 
models, and BIC for model selection to determine 
the number of clusters within the expression data. 
This step is the same as the model-based-clustering 
technique. (2) Using kurtosis to characterize features 
and find relevant classifiers. Depending on the sign of 
kurtosis,  major  bimodal  pattern  (negative  kurtosis) 
or outlier bimodal pattern (positive kurtosis) can be 
identified. PACK has been applied to number of cancer 
gene expression datasets in breast successfully.9,10 The 
use of kurtosis for identifying bimodally expressed 
genes, however, has a blind spot. If the proportions 
of samples in the two groups are close to a 20%–80% 
split,  then  the  kurtosis  is  close  to  zero.  Negative 
kurtosis strongly favors a perfect 50–50 split, which 
we think has a chance to miss biologically interesting 
genes. Positive kurtosis, on the other hand, shows a 
strong preference for extremely unbalanced splits on 
the order of 95–5 or even 99–1.
In this investigation, we propose an approach that 
replaces (or supplements) the use of AIC or BIC with 
a criterion that provides for finer distinctions between 
the  bimodally  expressed  genes.  By  assigning  a 
continuous value (the bimodality index) to each gene 
instead of a simple yes-or-no answer to the question 
of bimodality, we can provide researchers with a tool 
to rank genes and thus focus their interest on those 
with the strongest evidence of “useful” bimodality. 
We evaluate the estimation of the bimodality index 
of a set of measurements using both mixture model-
based  clustering  and  Markov  chain  Monte  Carlo 
(MCMC)  techniques  to  estimate  the  statistical 
parameters (means, standard deviation, and sample 
proportions)  of  the  mixture.  MCMC  sampling 
techniques  are  common  in  the  field  of  Bayesian 
analysis, and have emerged as popular tools for the 
analysis of complex statistical problems, including 
the analysis of microarray gene expression profiling 
data.11,12  We  apply  the  proposed  algorithm  to 
simulated  gene  expression  data  and  to  a  dataset 
from a microarray gene expression profiling study 
of breast cancer.
The Algorithm in Brief
We assume that, for a gene with bimodal expression, 
the distribution can be expressed as a mixture of two 
normal distributions:
  y N N = + - π µ σ π µ σ ( , ) ( ) ( , ) 1 1 2 2 1   (1)
where  y  is  the  expression  measurement;  π  is  the 
proportion of samples in one group; µ1 and µ2 are the 
means of the expression level of the two modes; and 
σ1 and σ2 are the standard deviations. In analyzing 
gene expression data, equal variance between groups 
is frequently assumed. If we assume that σ1 = σ2, the 
equation becomes
  y N N = + - π µ σ π µ σ ( , ) ( ) ( , ) 1 2 1   (2)
where  σ  is  the  common  standard  deviation.  We 
define the standardized distance, δ, between the two 
populations as
  δ
µ µ
σ
=
-
⋅
| | 1 2   (3)
For identifying genes with bimodal expression, the 
null hypothesis is δ = 0 and the alternative hypothesis 
is δ  0.
To illustrate how the shape of a bimodal density 
changes as π and δ vary (with σ = 1), we plotted a 
set of theoretical distributions. Figure 1a arranges the 
density plots in the δ - π plane. Because of symmetry 
in π from 0.0 to 1.0, we only illustrate the plots using 
π from 0.50–0.95. The plots indicate that bimodality is 
visually obvious when δ is sufficiently large or when 
the proportion π in each group is adequate. When 
π and δ reach certain critical values, bimodality is no 
longer visually distinguishable. The plots also suggest 
that the distinguishable bimodal patterns, as indicated 
by the plots in red in Figure 1a, are approximately 
bounded by a curve in the δ - π plane. Although this 
observation  about  distinguishability  is  subjective, 
it can be made objective by reference to a standard 
sample size computation.
Defining the bimodality index
Consider an experiment that involves two normally 
distributed  populations  with  means  µ1  and  µ2  and 
common standard deviation σ. The usual sample size 
computation tells us that the formula
  N
Z Z
=
+ 4 2
2
2
( )
,
/ α β
δ
  (4)Wang et al
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where zα /2 and zβ are the percentiles of the standard 
normal distribution that yield the desired significance 
and  power,  gives  the  total  number  N  of  samples 
needed to detect the standardized difference δ in an 
experiment with equal-sized groups. To achieve the 
same power with unequal sizes Mπ and M(1 - π), 
we should choose M to make the variance of the 
estimated  standardized  difference  with  unequal 
group  sizes  the  same  as  the  variance  with  equal 
sizes; that is,
 
1
1
1 1
1
1
2
1
2
4
π π π π ( ) ( ) / / -
= +
-
= + = ⋅
M M M N N N  
(5)
So, the total number of samples required when the 
groups are unequally sized is:
  M
Z Z
=
+
-
⋅
( )
( )
/ α β
π π δ
2
2
2 1
  (6)
Selecting  reasonable  values  for  α  and  β  for 
microarray experiments has been addressed by Simon 
et al,13 so we will not provide a detailed description 
here. Rearranging equation (6), we obtain
  π π δ
α β ( )
( ) / 1
2 2
2
- =
+
⋅
Z Z
M
  (7)
Motivated by equation (7), we define the bimodality 
index BI as
  BI = - ⋅ [ ( )]
/ π π δ 1
1 2
  (8)
In practice, we can estimate δ and π for a given 
dataset, then use these estimated values to compute BI.
Combinations  of  δ  and  π  that  give  the  same 
value of BI describe bimodal distributions that are 
“equally separable” in the sense that experiments to 
distinguish the two subgroups at a given significance 
and power would require the same total number of 
samples. The right hand side of equation (7) shows 
that larger values of BI correspond to smaller sample 
sizes and thus represent bimodal distributions that 
are  easier  to  distinguish.  Constant  BI  values  in 
equation (8) define curves in the δ - π space (Fig. 1b). 
Because of symmetry in π (0.0–1.0), we only show 
the plot for π from 0.5–1.0. The curves with constant 
bimodality index take on their minimum value at 
π = 0.5 (when the sizes of the two subgroups are the 
same), which gives the most power to distinguish 
a bimodal pattern for a given total sample size. When 
the group sizes are very unequal, for example, when 
π is close to 0.1 or 0.9, the power is much weaker 
for the same total sample size. Because the curve 
defined  by  BI = 1.1  perfectly  separates  the  red 
“visually bimodal” distribution curves from the black 
distribution  curves  in  Figure 1a,  we  recommend 
this  cutoff  to  select  bimodally  expressed  genes. 
Figure 1. relationships between bimodality and π and δ. (A) Density plots 
of bimodal data as π and δ vary. These plots indicate that bimodality is 
obvious when both π and δ are sufficiently large, but difficult to distinguish 
when π and δ reach certain values. The density plots colored red are 
“visually” distinguishable as bimodal measurements. (B) set of quadratic 
curves computed using different BI values; BI = 1.1 (blue), 1.2 (red), 
1.3 (green), 1.4 (brown), and 1.5 (purple).The bimodality index
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Other cutoffs can be chosen by using equations (7) 
and (8) to compute the sample size that would be 
needed to validate this degree of bimodality in an 
independent data set.
The  key  issue  that  remains,  then,  is  how  to 
accurately  estimate  the  parameters  δ  and  π  (and 
thus BI) from a given dataset. One approach is to 
use the expectation-maximization (EM) method for 
maximum-likelihood  estimation  in  parameterized 
normal mixture models. We can then combine the 
EM  method  for  mixture  estimation  with  BIC  for 
identifying  bimodal  distributions.  We  can  use  the 
R  package  MCLUST©  (University  of  Washington, 
Seattle, Washington), which follows this approach. 
We  refer  to  this  approach  as  a  normal  mixture-
model-based  clustering  algorithm.  Alternatively, 
we  can  use  MCMC  sampling  techniques  for  the 
estimation in a parameterized normal mixture model. 
We applied both algorithms to estimate the statistical 
parameters of the measurements. Then, based on the 
estimated parameters obtained from both algorithms, 
we computed BI in order to identify and rank more 
reliable bimodal patterns of expression. The difference 
between  the  two  algorithms  is  their  output:  the 
mixture model-based clustering technique provides 
point  estimates,  whereas  the  MCMC  technique 
provides  distributions  of  the  estimated  parameters. 
Knowing the distributions of the estimated parameters 
allows us to estimate the posterior probability of the 
classification of each sample.
simulation studies
To evaluate the performance of the bimodality index 
for  identifying  genes  with  meaningful  bimodal 
expression,  we  first  performed  simulation  studies. 
We adopted the R package MCLUST© (University 
of  Washington,  Seattle,  Washington),  to  perform 
mixture-model-based  clustering  and  to  obtain 
the  estimated  statistical  parameters.  From  these 
estimated  values,  we  computed  the  bimodality 
index BI for each measurement, and then selected 
bimodal measurements by setting a cutoff on the BI 
value. For comparison, we applied a hybrid MCMC 
technique to the same simulated dataset to estimate 
the  measurement  parameters  and  compute  BI.  To 
compute  BI,  we  used  point-estimated  parameters 
from  MCLUST  and  the  posterior  mean  estimates 
from MCMC.
Unimodally distributed measurements
To  obtain  unimodal  distributions,  we  generated 
expression datasets at four sample sizes: n = 50, 100, 
200, and 300. Each simulated dataset consisted of 
500 randomly  generated  samples  from  a  unimodal 
normal distribution, N(µ = 5, σ = 1). Such a study 
is used to evaluate the rate of false positives or to 
evaluate the specificity of the proposed method.
The results of our null simulation are presented 
in Table 1. When the sample size was sufficiently 
large (200), our proposed method using estimated 
parameters from either MCLUST or MCMC performed 
equally  well,  with  almost  no  false  discoveries. 
Similarly, the rate of false positives was low when 
using BIC. When the sample size was relatively small 
(n  100), the MCMC algorithm provided slightly 
better  results.  All  three  methods  performed  with 
high specificity in the simulated null datasets, which 
indicates very low rates of false positives.
Bimodally distributed measurements
Next, we evaluated the proposed method on simulated 
measurements that were truly bimodally distributed. 
Here the simulations are more elaborate, since δ and π 
will affect the “strength” or “reliability” of the bimodal 
expression. To fully evaluate the performance of the 
proposed method, we simulated expression datasets 
with different parameter settings.
Various δ with sufficient π in each group  
(π = 0.3–0.7)
To  evaluate  how  the  proposed  method  detected 
bimodal measurements for different values of δ, we 
simulated datasets as δ varied from 2 to 5. Here, δ  4 
indicates  a  strong  bimodal  pattern; δ  =  3  indicates 
a weak bimodal pattern; and δ = 2 corresponds to a 
very weak bimodal pattern. We assumed equal variance 
in  each  group.  For  simplicity,  we  set  σ1 = σ2 = 1, 
in which case δ is equivalent to ∆µ. We again used 
four sample sizes, n = 50, 100, 200, and 300. For 
this simulation, we let π range from 0.3 to 0.7 by 
steps of  0.1. For each π, we simulated 100 bimodal 
measurements.  Therefore,  we  had  500  bimodal 
variables associated with different values of π for each 
sample size. We applied both MCLUST and MCMC 
to estimate the statistical parameters µ1, µ2, σ, π, and δ. 
Based on these estimated parameters, we computed 
BI for each measurement.Wang et al
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Table 1. Performance in simulated null distributions (δ = 0).
sample sizes (n)  
(with 500 measurements)
Percentage of measurements identified as bimodal (false-positive rate) 
  BI cutoffs  McMc estimated  McLUsT estimated  BIc
50 1.1 0.8 1.8 2.6
1.2 0.2 1.4
1.3 0.0 1.4
1.4 0.0 1.2
1.5 0.0 0.8
100 1.1 0.4 1.2 1.6
1.2 0.2 0.8
1.3 0.2 0.8
1.4 0.0 0.4
1.5 0.0 0.0
200 1.1 0.0 0.4 0.6
1.2 0.0 0.4
1.3 0.0 0. 0
1.4 0.0 0.0
1.5 0.0 0.0
300 1.1 0.0 0.2 0.4
1.2 0.0 0. 0
1.3 0.0 0. 0
1.4 0.0 0. 0
1.5 0.0 0. 0
The  results  from  this  simulation  study  indicate 
that for a large δ (δ  4), the percentage of identified 
bimodal  measurements  using  MCLUST  was  close 
to  the  percentage  obtained  using  MCMC.  Both 
techniques demonstrated high accuracy (Table 2a). 
When δ = 5, the MCLUST algorithm facilitated the 
identification of the bimodal measurements with no 
false negatives (Fig. 2). This was also true when BIC 
was used. Even with a small sample size (n = 50) 
we were able to identify nearly all of the samples 
as  bimodal.  As  expected,  when  the  separation  of 
the  means  between  the  two  groups  was  large  and 
the sample population in each group was sufficient 
(30%  π  70%), any of the three methods allowed 
us to easily identify the bimodal measurements. For 
δ = 3,  the  identification  of  bimodal  measurements 
was the same using any of the three methods. When 
the sample size was small (n  50), all three methods 
identified about 50% of the bimodal measurements. 
As  the  sample  size  increased,  all  three  methods 
performed equally well and identified nearly 100% of 
the bimodal measurements.
When δ = 2, which indicates a very weak bimodal 
pattern and is slightly below our defined detection 
limit (bimodality index, BI = 1.1), we expect that most 
of the measurements will be identified as unimodal. 
Our  study  showed  that  only  a  few  measurements 
were identified as bimodal under this setting (Fig. 3 
and Table 2a). The results suggest that the MCMC 
method is slightly less sensitive than the MCLUST 
algorithm, but that the difference is almost negligible. 
Table 1 also shows that the BIC is more sensitive, 
especially  with  a  larger  sample  size.  This  is  not 
surprising. Because δ = 2, these simulations do arise 
from bimodal distributions. In effect, the BIC behaves 
like a cutoff on the bimodality index at a much smaller 
value than our limit of BI = 1.1 and thus will identify 
more samples as bimodal.The bimodality index
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Various δ with small proportions in one group 
(π = 0.1, 0.2, 0.25, or 0.8, 0.9)
We then focused on the issue of highly unbalanced 
group sizes (summarized in Table 2b). The findings 
indicate  that  the  bimodality  index  performed 
similarly  when  using  either  MCLUST  or  MCMC 
in  settings  with  a  strong  bimodal  pattern,  i.e. 
when δ was large (δ  4) and the sample size was 
sufficient (n  100). Using MCMC, the performance 
was  consistently  more  conservative.  The  BIC 
method  was  associated  with  a  higher  percentage 
of  identified  bimodal  measurements,  regardless 
of  the  sample  size.  The  study  also  indicated  that, 
when π was less than 0.1 or greater than 0.9 in one 
group,  some  bimodal  measurements  were  detected 
as unimodal (Fig. 4). In other words, when π  0.1 
or π  0.9 and the sample size is small (n  100), 
even when δ is sufficiently large, the false-negative 
rate will be high.
Application to cancer Microarray 
Gene expression Measurements
Microarray gene expression measurements are more 
complicated  than  simulated  data.  To  evaluate  the 
Using model-based clustering algorithm (MCLUST) Using McMc
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Figure 2. Performance of the proposed method with MCLUsT and MCMC techniques in a simulated strong bimodal measurement dataset, δ = 5 and 
π = 0.3–0.7. The dataset contains 50 samples and 500 measurements. The black spots represent individual measurement, and blue clouds indicate 
the density of each data point. The set of quadratic curves computed using different BI values; BI = 1.1 (blue), 1.2 (red), 1.3 (green), 1.4 (brown), 
and 1.5 (purple).
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Figure 3. Performance of the proposed method with MCLUsT and MCMC in simulated bimodal dataset, with δ = 2 and π = 0.3–0.7. The dataset contains 
50 samples and 500 measurements. The set of quadratic curves computed using different BI values; BI = 1.1 (blue), 1.2 (red), 1.3 (green), 1.4 (brown), 
and 1.5 (purple).Wang et al
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Table 2a. Results from simulated bimodal data set, with sufficient sample sizes in each subgroup (Proportion in one group 
π = 0.3 to 0.7, in 0.1 intervals).
  
sample sizes (n) 
(data = 500 × n)
BI cutoffs Identified bimodal (%)  
δ = 2 δ = 3   δ = 4 δ = 5
McMc 
estimated
McLUsT 
estimated
BIc  
selected
McMc 
estimated
McLUsT 
estimated
BIc 
selected
McMc 
estimated
McLUsT 
estimated
BIc 
selected
McMc 
estimated
McLUsT 
estimated
BIc 
selected
50 1.1 6.0 8.2 8.8 47.6 50.0 50.0 93.6 98.4 98.4 100 96.2 100
1.2 4.0 8.8 40.2 49.8 92.0 98.4 100 96.2
1.3 2.8 7.6 33.4 49.6 89.8 98.2 100 96.0
1.4 1.4 6.8 26.6 47.4 85.8 97.6 100 95.8
1.5 0.6 5.8 17.8 43.6 78.8 95.0 100 95.6
100 1.1 6.6 8.8 9.6 77.2 83.2 83.2 99.4 100 100 100 99.4 100
1.2 3.2 8.4 67.0 82.0 98.8 100 100 99.4
1.3 1.2 6.0 53.8 76.8 98.2 99.8 100 99.4
1.4 0.4 2.8 37.8 63.4 96.6 99.0 100 99.2
1.5 0 1.4 23.2 43.2 94.2 97.6 100 99.2
200 1.1 5.4 13.2 17.2 91.6 97.4 98.0 99.8 100 100 100 100 100
1.2 2.0 9.0 83.8 95.4 99.8 100 100 100
1.3 0.4 2.0 70.6 85.4 99.8 100 100 100
1.4 0.2 0.2 48.2 66.4 99.6 99.8 100 100
1.5 0 0 23.6 40.4 99.3 99.8 100 100
300 1.1 7.8 18.2 27.6 94.8 99.8 100 99.8 100 100 100 100 100
1.2 2.6 8.2 88.6 97.0 99.8 100 100 100
1.3 0.4 1.8 73.8 85.6 99.8 100 100 100
1.4 0 0 47.8 63.6 99.8 100 100 100
1.5 0 0 22.4 35.2 99.8 100 100 100
usefulness  of  our  proposed  method  for  identifying 
genes  with  bimodal  expression,  we  applied  the 
algorithm to a dataset of microarray gene expression 
profiles from a study of breast cancer.
Briefs of expression profiling  
and data processing
The  gene  expression  profiling  array  dataset  was 
produced  by  the  Breast  Cancer  Pharmacogenomic 
Program at The University of Texas M. D. Anderson 
Cancer Center using Affemetrix U133A GeneChip. 
The  dataset  contains  133  human  breast  cancer 
samples,  with  each  array  containing  22,283  probe 
sets. (The expression profiles and clinical information 
are  available  at  http://bioinformatics.mdanderson.
org/pubdata.html.)  The  original  purpose  of  the 
investigation was to develop multi-gene predictors of 
pathologic complete response (pCR) to preoperative 
therapy.14 The clinical variables associated with the 
dataset include disease stage, histologic grade, and 
routine clinical markers such as the estrogen receptor 
(ER), the human epidermal growth factor receptor 2 
(HER-2), and the progesterone receptor (PR) status. 
Response  to  preoperative  chemotherapy  was  also 
available.
For  gene  expression  measurements,  the  signal 
intensities at the level of the probe sets were quantified 
by dChip 1.3 (http://dchip.org) using the PM-model 
only. Normalization was performed by dChip using 
the  array  with  median  brightness.  The  normalized 
expression measurement was logarithm transformed 
(base  2)  for  analysis.  Because  the  expression  data 
were produced on different dates, we considered the 
possibility of a “batch effect,” which occurs as a result 
of  differences  in  the  hybridization  environment  on 
different days. Although common in microarray gene The bimodality index
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Table 2a. Results from simulated bimodal data set, with sufficient sample sizes in each subgroup (Proportion in one group 
π = 0.3 to 0.7, in 0.1 intervals).
  
sample sizes (n) 
(data = 500 × n)
BI cutoffs Identified bimodal (%)  
δ = 2 δ = 3   δ = 4 δ = 5
McMc 
estimated
McLUsT 
estimated
BIc  
selected
McMc 
estimated
McLUsT 
estimated
BIc 
selected
McMc 
estimated
McLUsT 
estimated
BIc 
selected
McMc 
estimated
McLUsT 
estimated
BIc 
selected
50 1.1 6.0 8.2 8.8 47.6 50.0 50.0 93.6 98.4 98.4 100 96.2 100
1.2 4.0 8.8 40.2 49.8 92.0 98.4 100 96.2
1.3 2.8 7.6 33.4 49.6 89.8 98.2 100 96.0
1.4 1.4 6.8 26.6 47.4 85.8 97.6 100 95.8
1.5 0.6 5.8 17.8 43.6 78.8 95.0 100 95.6
100 1.1 6.6 8.8 9.6 77.2 83.2 83.2 99.4 100 100 100 99.4 100
1.2 3.2 8.4 67.0 82.0 98.8 100 100 99.4
1.3 1.2 6.0 53.8 76.8 98.2 99.8 100 99.4
1.4 0.4 2.8 37.8 63.4 96.6 99.0 100 99.2
1.5 0 1.4 23.2 43.2 94.2 97.6 100 99.2
200 1.1 5.4 13.2 17.2 91.6 97.4 98.0 99.8 100 100 100 100 100
1.2 2.0 9.0 83.8 95.4 99.8 100 100 100
1.3 0.4 2.0 70.6 85.4 99.8 100 100 100
1.4 0.2 0.2 48.2 66.4 99.6 99.8 100 100
1.5 0 0 23.6 40.4 99.3 99.8 100 100
300 1.1 7.8 18.2 27.6 94.8 99.8 100 99.8 100 100 100 100 100
1.2 2.6 8.2 88.6 97.0 99.8 100 100 100
1.3 0.4 1.8 73.8 85.6 99.8 100 100 100
1.4 0 0 47.8 63.6 99.8 100 100 100
1.5 0 0 22.4 35.2 99.8 100 100 100
expression  profiling  investigations,  the  batch  effect 
necessitates correction of the data. In order to obtain 
meaningful  results,  we  performed  a  gene-by-gene 
adjustment of the means to put the batches created 
on two different dates on the same scale. Briefly, we 
adjusted the means on each gene from one batch to 
match the means of the same genes in the other batch.
Identifying genes with bimodal 
expression
Once data processing was complete, we applied the 
proposed  method  with  the  MCLUST  and  MCMC 
algorithms  to  identify  the  genes  with  bimodal 
expression. In both approaches, we estimated µ1, µ2, 
σ, π, and δ from the expression measurement of each 
gene across all samples, and computed BI for each 
gene. Figure 5 shows the genes from the breast cancer 
dataset identified as having bimodal expression.
Microarray gene expression profiling data contain 
significant levels of technical and biologic variation. 
Many measurements are just “noise,” containing no 
useful information. In order to identify genes with 
interesting  expression  patterns,  it  is  common  to 
apply a filtering criterion to eliminate some “noise.” 
The selection of a filtering condition involves some 
subjectivity. In this investigation, we filtered at several 
different levels. Specifically, we first computed the 
expression levels at several percentiles (0.25, 0.30, 
0.35,  0.40,  0.45,  and  0.50)  using  all  expression 
measurements across all samples. We then computed 
the maximum expression value of each gene across 
all  samples.  If  the  maximum  was  less  than  the 
expression level at a selected filtering percentile, we 
considered that expression measurement to be “noise” 
and  eliminated  it  from  the  analysis.  For  example, 
the overall 25th percentile of expression was 6.771. Wang et al
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Table 2b. results from simulated bimodal data set, with small sample size in one subgroup (Proportion in one group, 
π = 0.1, 0.2, 0.25, 0.8, 0.9).
  
sample sizes (n)  
(data = 500 × n)
BI cutoffs Identified bimodal (%)         
 
       
δ = 2  δ = 3      δ = 4  δ = 5
      McMc 
estimated
McLUsT 
estimated
BIc  
selected
McMc 
estimated
McLUsT 
estimated
BIc  
selected
McMc  
estimated
McLUsT 
estimated
BIc  
selected
McMc  
estimated
McLUsT 
estimated
BIc 
selected
50 1.1 4.8 8.0 11.0 25.2 43.6 51.4 58.2 83.0 91.6 69.4 93.6 98
1.2 2.0 7.0 18.8 39.2 52.2 77.4 67.8 91.0
1.3 1.0 5.4 13.2 32.2 45.8 69.0 65.2 87.8
1.4 0.8 3.6 7.8 22.2 38.0 59.6 60.8 83.6
1.5 0.0 2.6 5.4 14.0 31.2 48.6 56.2 77.4
100 1.1 2.8 5.8 11.0 31.8 48.6 77.2 75.8 87.8 98.4 85.6 97.2 100
1.2 1.8 3.4 21.2 37.0 69.8 79.8 84.2 94.8
1.3 0.8 2.0 13.2 24.5 60.0 71.4 80.8 91.6
1.4 0.2 1.4 6.6 14.4 51.6 61.4 77.0 87.8
1.5 0 0.2 1.6 7.0 39.6 50.4 71.4 81.6
200 1.1 0.2 3.6 23.2 41.4 53.6 95.8 80.4 90.4 100 89.9 99.6 100
1.2 0 0.4 27.4 39.4 72.2 80.0 88.0 98.0
1.3 0 0 12.4 21.0 63.6 69.6 85.4 93.8
1.4 0 0 5.4 9.2 53.8 60.4 79.8 88.6
1.5 0 0 1.8 3.6 43.2 49.8 74.0 81.0
300 1.1 0.2 2.4 35.0 46.4 55.4 99.6 83.8 91.8 100 90.8 99.8 100
1.2 0 0 26.4 38.2 72.8 81.4 89.4 99.4
1.3 0 0 12.0 16.8 64.0 69.2 86.8 96.6
1.4 0 0 3.0 5.4 56.0 60.2 80.0 90.0
  1.5 0 0   0.2 0.4   46.4 52.4   71.8 79.9  
If a gene had a maximum expression of less than 6.771, 
we removed that gene from the analysis. Once the 
“noise” measurements were filtered out, we performed 
the analysis for identifying bimodal measurements 
using the MCLUST and MCMC techniques at each 
of the defined filtering percentiles and at each of the 
BI values. The results are summarized in Table 3.
The results show that using our method combined 
with MCLUST identified more genes with bimodal 
expression  than  using  our  method  combined  with 
MCMC at the same filtering conditions and the same 
bimodality  index  cutoff.  This  suggests  again  that 
MCLUST is more sensitive than MCMC. However, 
at every level of the bimodality index and at every 
filtration level based on a more stringent definition 
of noise, a larger percentage of the genes identified 
by MCMC remain above the noise, as compared to 
MCLUST. We also compared the genes with bimodal 
expression  that  were  identified  from  our  method 
combined  with  the  MCMC  versus  the  MCLUST 
algorithms. The results from that comparison show 
extensive overlap in the genes identified with bimodal 
expression  by  both  algorithms  (see Table  4). This 
suggests that using our method with either technique 
yields similar results when estimating the statistical 
parameters and computing the bimodality index for 
detecting genes with bimodal expression.
The results also show that vastly more genes (often 
by an order of magnitude) were identified as bimodal 
using BIC, but a smaller percentage of these genes 
remain  above  the  filtration  noise  cutoffs.  Because 
the bimodality index for these genes is small, this 
finding  strongly  suggests  that  the  majority  of  the 
genes identified by BIC either have small separations The bimodality index
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Table 2b. results from simulated bimodal data set, with small sample size in one subgroup (Proportion in one group, 
π = 0.1, 0.2, 0.25, 0.8, 0.9).
  
sample sizes (n)  
(data = 500 × n)
BI cutoffs Identified bimodal (%)         
 
       
δ = 2  δ = 3      δ = 4  δ = 5
      McMc 
estimated
McLUsT 
estimated
BIc  
selected
McMc 
estimated
McLUsT 
estimated
BIc  
selected
McMc  
estimated
McLUsT 
estimated
BIc  
selected
McMc  
estimated
McLUsT 
estimated
BIc 
selected
50 1.1 4.8 8.0 11.0 25.2 43.6 51.4 58.2 83.0 91.6 69.4 93.6 98
1.2 2.0 7.0 18.8 39.2 52.2 77.4 67.8 91.0
1.3 1.0 5.4 13.2 32.2 45.8 69.0 65.2 87.8
1.4 0.8 3.6 7.8 22.2 38.0 59.6 60.8 83.6
1.5 0.0 2.6 5.4 14.0 31.2 48.6 56.2 77.4
100 1.1 2.8 5.8 11.0 31.8 48.6 77.2 75.8 87.8 98.4 85.6 97.2 100
1.2 1.8 3.4 21.2 37.0 69.8 79.8 84.2 94.8
1.3 0.8 2.0 13.2 24.5 60.0 71.4 80.8 91.6
1.4 0.2 1.4 6.6 14.4 51.6 61.4 77.0 87.8
1.5 0 0.2 1.6 7.0 39.6 50.4 71.4 81.6
200 1.1 0.2 3.6 23.2 41.4 53.6 95.8 80.4 90.4 100 89.9 99.6 100
1.2 0 0.4 27.4 39.4 72.2 80.0 88.0 98.0
1.3 0 0 12.4 21.0 63.6 69.6 85.4 93.8
1.4 0 0 5.4 9.2 53.8 60.4 79.8 88.6
1.5 0 0 1.8 3.6 43.2 49.8 74.0 81.0
300 1.1 0.2 2.4 35.0 46.4 55.4 99.6 83.8 91.8 100 90.8 99.8 100
1.2 0 0 26.4 38.2 72.8 81.4 89.4 99.4
1.3 0 0 12.0 16.8 64.0 69.2 86.8 96.6
1.4 0 0 3.0 5.4 56.0 60.2 80.0 90.0
  1.5 0 0   0.2 0.4   46.4 52.4   71.8 79.9  
between  the  modes  or  have  highly  imbalanced 
proportions of samples in the two groups. Figure 6 
illustrates that 70% of genes called bimodal by BIC 
that have BI  1.1 also have π  10%, and 97% of 
these genes have π  20%. Thus, most of these genes 
are driven by a relatively small number of samples 
in one of the two groups.
Example of genes identified as having 
bimodal expression in the human breast 
cancer data
With known clinical information from the dataset, we 
checked three probesets related to three breast cancer 
genes, ERS1, PGR and HER2, which we expect to 
be  expressed  bimodally  in  our  dataset.  Previous 
investigation  suggested  that  the  three  selected 
probesets correspond to the three genes strongly.15–17 
In addition to the three known genes in breast cancer, 
we also present here two bimodal genes (CKB and 
BST2) discovered by our method.
The first example is the estrogen receptor (ERS1) 
with  probe  set  ID  205225_at.  From  a  previous 
analysis, we know that this probe set correlates highly 
with the clinical estrogen receptor status.16 Figure 7 
illustrates the density plot for the ERS1 gene (top left). 
The estimated parameters are provided in Table 5. 
The point estimate is BI = 1.955 and the posterior 
probability  of  being  bimodal  is  99.9%  (based 
on BI = 1.1). This value of BI was the 16th largest 
among the 22,283 probe sets on the array. The clinical 
information associated with this experiment indicates 
that there are 51 patient samples with negative ER 
status and 82 patient samples with positive ER status 
in this dataset. The estimated proportions are close to Wang et al
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Figure 4. Performance of the proposed method with MCLUsT and MCMC techniques in a simulated bimodal dataset, with δ = 4 and π = 0.1, 0.2, 0.25, 
0.8 and 0.9. The simulated dataset contains 50 samples and 500 measurements. The set of quadratic curves computed using different BI values; BI = 1.1 
(blue), 1.2 (red), 1.3 (green), 1.4 (brown), and 1.5 (purple).
π
δ
0.0 0.2 0.4 0.6 0.8 1.0
1
0
1
5
0
5
Figure 5. Genes identified with bimodal expression from breast cancer 
dataset. The significant genes with bimodal expression are circled in 
purple. The π represent the population sizes; δ is the difference between 
the means divided by standard deviation (σ). equal variance in both 
groups is assumed. The curve represents BI = 1.1.
the clinical ER status obtained from both the MCMC 
and MCLUST techniques. In comparison, MCLUST 
provided slightly better results.
The  second  example  of  a  gene  with  bimodal 
expression involves the progesterone receptor (PGR), 
for which the probe set ID is 208305_at. PGR is an 
intercellular steroid receptor that specifically binds 
progesterone  and  is  located  at  11q22.  The  point 
estimate is BI = 1.733, and the posterior probability 
of it being bimodal is 100%. The density plot of PGR 
is illustrated in Figure 7 (middle left). The estimated 
measurement parameters are provided in Table 4. The 
clinical information indicates that the dataset contains 
information on 55 patient samples with positive PGR 
status, 75 patient samples with negative PGR status, 
and 3 patient samples with unknown PGR status. The 
estimated proportions in each group are close to those 
of the true sub-population (see Table 5).
The  third  example  of  bimodal  gene  expression 
involves  the  human  epidermal  growth  factor 
receptor 2 (ERBB2 or HER2), for which the probe 
set ID is 216836_s_at.15,17 HER2 is important for its 
role in the pathogenesis of breast cancer and as a 
current target of treatment. The density plot of HER2 
is illustrated in Figure 7 (bottom left). The estimated 
measurement  parameters  are  provided  in  Table  5. 
The point estimate is BI = 1.634 and the posterior 
probability  of  HER2  being  bimodal  is  99.9% 
(at BI = 1.1). The clinical information indicates that 
the dataset includes information on 33 patient samples 
with positive HER2 tumor status, 99 patient samples 
with  negative  HER2  status,  and  one  patient 
sample with unknown HER2 status. The estimated 
proportions in each group approximate those of the 
true  sub-population.  The  results  from  these  three 
examples strongly indicate that the proposed method The bimodality index
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works  accurately  with  the  MCMC  and  MCLUST 
algorithms. Importantly, all three of these bimodally 
expressed genes represent therapeutic targets for anti-
estrogen and anti-HER2 therapies that are currently 
used in the clinic. We hope that the other bimodally 
expressed genes contain similarly important but novel 
drug targets.
In addition to the three “standard” breast cancer 
therapeutic target genes, we present two bimodal genes 
identified by our method, but previously unreported. 
The two genes are (1) Creatine kinase, brain (CKB; 
with probe set ID 200884_at), and (2) Bone marrow 
stromal  cell  antigen  2  (BST2;  with  probe  set  ID 
201641_at).  Both  genes  exhibit  strong  bimodal 
patters, with bimodality index 1.619 for CKB and 
1.602 for BST2 (Fig. 8). Their roles in breast cancer 
are poorly understood and further investigation will 
be carried out.
Identifying genes with strong  
bimodal expression
We also applied more stringent conditions to identify 
genes with bimodal expression. Using BI  1.5 as 
a  cutoff  and  without  filtering,  we  identified  181 
and 213 genes with bimodal expression using the 
MCMC  and  MCLUST  algorithms,  respectively. 
There  were  151 genes  with  bimodal  expression 
that were identified using both algorithms. To test 
the  hypothesis  that  bimodally  expressed  genes 
could  be  used  as  outcome  or  disease  phenotype 
markers,  we  performed  two-way  hierarchical 
cluster analysis using these 151 genes (Fig. 9). The 
results of the analysis suggest that the genes with 
the strongest bimodal expression are closely related 
to two clinical types of breast cancers: ER-positive 
cancers  and  ER-negative  cancers.  As  these  two 
neoplastic diseases of the breast may originate from 
different  cell  types  (luminal  and  basal  epithelial 
cells, respectively) this association is not surprising 
and supports the validity of our method.18 We also 
correlated the clusters with HER2 status and with 
patient  response  to  treatment,  recorded  as  either 
pCR or residual disease (RD) (see Fig. 10). As noted, 
the major split in the dendrogram correlates with 
hormone  receptor  status.  The  second  split  in  the 
dendrogram  correlates  with  HER-2  status.  These 
associations have already been noted in the clinical 
literature.17  However,  correlations  between  these 
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routine clinical markers and the other genes on our 
list will warrant further biological exploration.
Discussion and conclusions
In this paper, we have introduced a new approach 
to identifying and ranking meaningful and reliable 
bimodal  measurements  from  large-scale  gene 
expression measurements. The key to this approach 
is  to  define  a  bimodality  index  that  provides  an 
objective measure of the “strength” of the bimodal 
separation.  Comparing  with  AIC  or  BIC,  the 
major difference is that our approach is not just for 
selecting bimodal genes, but also ranks the genes. 
The bimodality index can be evaluated empirically, 
and its interpretation is justified by standard sample 
size and power calculations. To apply this method to 
large-scale gene expression data, we need to estimate 
the model parameters µ1, µ2, σ, and π in order to 
compute the bimodality index BI. Suitable techniques 
for performing such an analysis include a mixture-
model-based  clustering  technique  and  the  MCMC 
technique.
When applying a mixture-model-based clustering 
technique,  the  number  of  components  (clusters) 
needs to be predefined. For bimodal measurements, 
a  two-component  mixture  model  is  applied.  The 
model fits the data with a mixture of two normal 
distributions,  and  provides  point  estimations  of 
the measurement parameters µ1, µ2, σ, and π. The 
estimated  parameters  are  then  used  to  compute 
the  bimodality  index.  The  major  advantage  of 
the  mixture-model-based  clustering  technique  is 
computational  efficiency.  For  large-scale  gene 
expression data, that process can be completed in a 
very short time with high accuracy in the estimated 
parameters.
The  advantage  of  the  MCMC  technique  is  that 
it  provides  distributions  of  the  parameters  µ1, 
µ2, π, and σ. Applying the MCMC technique with 
our method, we can use either the posterior mean 
or  the  full  posterior  distribution  of  the  bimodality 
index. Because the process involves estimating the 
distributions, the MCMC technique takes longer and 
is more computationally intensive. This increased time 
can  be  especially  problematic  for  large-scale  gene 
expression data, which makes MCMC less popular 
in  the  analysis  of  high-throughput  genomic data. 
Table 4. Commonly identified bimodal genes using proposed method and with MCMC and MCLUST.
Quantiles set for filtering Bimodality Index cutoffs
BI = 1.1 BI = 1.2 BI = 1.3 BI = 1.4 BI = 1.5
0.00 1113 673 397 235 151
0.25 1077 664 393 233 150
0.30 1057 653 390 233 150
0.35 1036 646 387 232 149
0.40 1012 637 384 232 149
0.45 967 617 372 228 149
0.50 919 590 361 224 147
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Figure 6. histogram of the proportion of samples in the smaller of two 
groups for genes that were called bimodal by BIC in the breast cancer 
dataset but had BI  1.1.The bimodality index
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That problem, however, can be overcome by using 
a parallel processor system, which involves breaking 
the expression dataset into several small subsets and 
performing the analysis in parallel for each subset. 
In  this  way,  the  MCMC  algorithm  can  be  carried 
out in a relatively short time. Although a number of 
MCMC algorithms are available, we only applied one 
MCMC technique in this investigation. We chose the 
hybrid MCMC technique because it is not difficult 
to implement and was readily available. (We did not 
intend to evaluate which of the MCMC algorithms 
performed better).
One potential objection to our method is that it 
assumes both components are normally distributed 
with the same variance. Both model-based clustering 
via the EM algorithm and MCMC techniques can be 
extended to use mixtures of t-distributions19 or mixtures 
of  other  distributions. As  long  as  the  distributions 
being  used  have  a  “central  parameter”  that  plays 
the role of the mean for the normal distribution, the 
definition  of  the  bimodality  index  proposed  here 
carries over directly to these more general mixture 
distributions.  One  can  also  accommodate  different 
standard  deviations  by  defining  the  standardized 
distance  between  means  to  be δ µ σ µ σ = - | / / |. 1 1 2 2  
The performances of these kinds of extensions to the 
method deserve further study.
We  evaluated  the  sensitivity  and  specificity  of 
the  proposed  method  in  identifying  meaningful 
bimodal  measurements  through  simulation  studies. 
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Figure 7. Left panel: histograms of three identified bimodally expressed genes from breast cancer dataset; estrogen receptor (top), progesterone receptor 
(middle), and her-2 (bottom). Right panel: posterior distributions of bimodality index on the three genes, computed using MCMC. The vertical blue lines 
indicate the point estimated bimodality index value from MCLUsT. The red lines are the density estimations.Wang et al
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We compared the results of computing the bimodality 
index  by  two  different  algorithms,  MCLUST  and 
MCMC. We also compared the results obtained from 
our method with those obtained from the commonly 
used  BIC.  Due  to  the  similarity  in  application 
between AIC and BIC, we did not include AIC in the 
comparison. In the null distribution, the results were 
quite  similar;  all  methods  had  few  false  positives. 
In  addition  to  the  null  distribution,  we  evaluated 
bimodal  patterns  with  various  parameter  settings. 
Those simulations indicate that, although BIC is more 
sensitive for detecting bimodal distributions, using 
the  bimodality  index  provides  fine-grained  control 
over the discoveries, allowing the researcher to rank 
the  genes  by  their  degree  of  bimodality  and  thus 
focus attention on the genes whose bimodal patterns 
are most believable and most likely to be clinically 
useful.
We  further  applied  our  proposed  method  to  a 
dataset from a breast cancer gene expression profiling 
study. Unlike simulated data, actual gene expression 
data is far more complex and contains a high level 
of noise; therefore we expected a much higher rate 
of false discovery in that analysis, particularly when 
the size of one of the groups was small. When we 
applied the mixture-model-based clustering technique 
with BIC, over 35% of the genes were identified as 
bimodal. We tried to remove some noise prior to the 
analysis by setting various filtering conditions. After 
filtering,  we  still  identified  a  substantial  number 
of  bimodal  measurements  when  using  BIC.  We 
then applied our method to the filtered datasets. In 
contrast, our method produced much more reasonable 
results, which suggests that it is a useful approach 
for  the  analysis  of  real  datasets.  Moreover,  the 
filtering process helped to remove some unreliable 
measurements  for  small  values  of  BI  (BI    1.3). 
For a strong bimodal pattern (BI  1.4), the results 
indicate that the bimodal measurements identified in 
this  process  were  almost  unchanged,  regardless  of 
whether or not the filtering conditions were applied. 
Further, the genes identified as most strongly bimodal 
appeared to be related to the hormone receptor (ERS1 
and PGR) status and HER2 status of the breast cancer 
patients.  Since  these  characteristics  are  known  to 
be strong determinants of both gene expression and 
Table 5. estimated parameters for ers, her2 and Pgr genes.
Genes estimated from McMc estimated from McLUsT
µ1 µ2 σ δ π1 and π2 µ1 µ2 σ δ π1 and π2
eRs1 6.90 10.79 1.00 3.90 40.9% and 60.1% 6.88 10.79 0.97 4.02 38.4% and 61.6%
HeR2 9.36 12.68 0.86 3.89 19.0% and 81.0% 9.34 12.63 0.83 3.97 21.6% and 78.4%
pGR 4.62 6.98 0.62 3.84 26.8% and 73.2% 4.62 6.98 0.60 3.95 26.0% and 74.0%
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Figure 8. histograms of two bimodally expressed genes in breast cancer: Creatine kinase, brain (left), and Bone marrow stromal cell antigen 2 (right). 
The roles of these two genes in breast cancer chemotherapeutic treatment were not reported previously.The bimodality index
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response to specific treatments in breast cancer, this 
finding  provides  evidence  that  using  our  method 
has the potential to focus on biologically important 
subsets of gene expression profiling data.
In  addition  to  finding  the  expected  genes,  we 
described two additional genes (CKB and BST2) that 
exhibit  strong  bimodal  expression  patterns  within 
breast  cancer  samples.  Creatinine  kinase,  brain 
(CKB) is a cytoplasmic enzyme involved in energy 
homeostasis. It acts as a homodimer (CK-BB) in brain 
as well as in other tissues, and as a heterodimer with 
a similar muscle isozyme (CKM) in heart. Rubrey et al 
reported that 34% of breast cancer patients showed 
elevated serum levels of the CK-BB homodimer, and 
that an increased incidence of elevated serum CK-BB 
levels was associated with advanced stage disease.20 
Using a more sensitive assay, Zarghami et al measured 
CK-BB levels in breast tumor cytosols and found that 
CK-BB was associated with more aggressive tumors 
but concluded that its value as a prognostic indicator 
was limited.21
Bone  marrow  stromal  cell  antigen  2  (BST2  or 
CD317)  was  originally  recognized  as  a  surface 
antigen on bone marrow stromal cell lines; however, 
it is predominantly expressed in liver, lung, heart, 
and placenta, and not typically expressed in normal 
breast.  Becker  et al  using  Affymetrix  HuGeneFL 
and  Hu95Av2  microarray  experiments,  identified 
BST2 as significantly up-regulated in a tamoxifen-
resistant cell line derived from the mammary tumor 
cell line MaCa 3366.22 Recently, Cai et al reported 
that  BST2  is  up-regulated  in  breast  cancer  with 
bone metastasis, and concluded that BST2 may be 
a  potential  biomarker  in  breast  cancer  with  bone 
metastasis.23
Our  method  performed  reasonably  well  in 
revealing  meaningful  bimodal  patterns  of  gene 
expression in comparison with the commonly-used 
BIC approach. The results from the analyses suggest 
that  our  proposed  method  is  a  sensible  approach 
for the analysis of large-scale gene expression data, 
and can be extended for broad application.
Author’s contributions
KRC and JW derived background method, designed 
the  investigation,  performed  the  analyses,  and 
prepared the manuscript. LP and WFS participated 
in  conducting  breast  cancer  pharmacogenomic 
clinical trial and collected all biopsies for the study. 
SJW technical programming support and performed 
analyses.
Acknowledgements
Funding: This research was supported in part by the 
National Cancer Institute [P50 CA116199]; and the 
United  States  Department  of  Defense  [W81XWH-
07-1-0306 and W81XWH-04-1-0142].
Figure 9. heat map image produced using 151 genes with strong bimodal 
expression as commonly identified by MCMC and MCLUST from 133-array 
breast cancer dataset. Two distinct sample clusters can be seen. One 
cluster contains mainly er positive tumor samples (blue color bar) and the 
other cluster contains mostly er negative tumor samples (red color bar).
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Figure 10. hierarchical cluster analysis using 151 genes with “strong” 
bimodal  expression  as  commonly  identified  by  MCMC  and  MCLUST 
algorithms. The color codes correlate the er, her-2, Pr and pCr, and 
rD status of the tumor.Wang et al
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